Acute Chest Syndrome Clinical Trial
Official title:
Investigator-initiated, Placebo-controlled, Randomized Trial to Assess the Efficacy and Safety of Platelet Inhibition and/ or Lipid Lowering in Non-ACS-patients With Elevated High-sensitivity Troponin Values
The study evaluates the effect of platelet inhibition and / or lipid lowering in non-ACS-patients with symptoms suggestive for ACS, and elevated high-sensitivity troponin values
Current databases show, that high-/ ultra sensitive (hs)/ (us) troponin levels above the 99th percentile in patients presenting with chest pain are indicative for future cardiovascular events, even when acute coronary syndrome (ACS) was ruled out. Most of these non-ACS-patients are discharged without specific/ preventive therapy (anti-platelet or anti-lipid), although "positive" troponin values (any value at any time during hospitalisation above the 99th percentile) seem to clearly indicate underlying myocardial ischemia. In summary, there is an unmet need and huge potential to reduce mortality and morbidity in Chest Pain Unit patients by specific therapy. The investigators propose that platelet inhibition by Aspirin or lipid lowering by Atorvastatin will prevent plaque rupture and superimposition of thrombosis to coronary atherosclerosis in this population. It is planned to conduct a controlled clinical trial: 3,000 troponin positive patients presenting at emergency room (ER)/ CPU with symptoms suggestive for ACS, but an ACS was ruled out, will be assigned randomly to Aspirin 100 mg and/ or Atorvastatin 20 mg versus placebo (2x2 factorial design). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 | |
| Active, not recruiting |
NCT04170348 -
Daily Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
| Recruiting |
NCT03498105 -
Utility of the Cardiac Electrical BiomarkerDisease
|
||
| Terminated |
NCT02098993 -
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT06214845 -
Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease
|
N/A | |
| Completed |
NCT02187445 -
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
|
Phase 1 | |
| Completed |
NCT01089439 -
Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
|
Phase 2 | |
| Completed |
NCT03919266 -
Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.
|
N/A | |
| Terminated |
NCT01589926 -
Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
|
N/A | |
| Completed |
NCT01041339 -
ST Elevation in Acute Chest Pain; Could Measurement of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) be Helpful to the Clinician?
|
N/A | |
| Completed |
NCT03250585 -
sPLA2 in EBC During Acute Chest Syndrome
|
||
| Completed |
NCT03805581 -
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
|
Phase 2 | |
| Recruiting |
NCT03032055 -
Validation of a Predictive Score of Acute Chest Syndrome
|
||
| Completed |
NCT00748423 -
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
|
Phase 2/Phase 3 | |
| Completed |
NCT00434473 -
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
|
Phase 2 | |
| Completed |
NCT02580773 -
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
|
Phase 3 | |
| Completed |
NCT01443728 -
Vitamin D for Sickle-cell Respiratory Complications
|
Phase 2 | |
| Recruiting |
NCT05640271 -
Tocilizumab for Acute Chest Syndrome
|
Phase 2 |